Scholarlink

Background <p>Pharmacologic therapies for heart failure with preserved ejection fraction (HFpEF) have shown limited efficacy, and the impact of GLP-1 receptor agonists (GLP-1 RAs) remains unclear. This meta-analysis evaluates their effects on mortality and hospitalization in HFpEF.</p> Methods <p>We obtained the data from PubMed, Scopus, Embase, and Web of Science for all eligible studies, including clinical trials (RCT) and cohorts comparing GLP-1 RAs to placebo or other hypoglycemic agents in patients with HFpEF published until December 31st, 2024. The Grade and Risk of Bias (ROB) tool assessment was used to evaluate the quality of the evidence. Data on the primary outcome, the composite of all-cause mortality and HF-related hospitalization, was pooled using a random effect meta-analysis with additional subgroup analyses. Risk ratios (RR), hazard ratios (HR), or mean differences with 95% confidence intervals (CI) are presented accordingly.</p> Results <p>Six studies (five RCTs, one cohort) including 4043 patients were analyzed. Five studies evaluated semaglutide and one tirzepatide. GLP-1 RAs reduced the composite outcome of all-cause mortality and HF hospitalization by 27% (HR 0.73; 95% CI: 0.60–0.90; <i>I</i><sup>2</sup> = 0%). Subgroup analyses revealed greater benefits in patients with atrial fibrillation. GLP-1 RAs also reduced HF hospitalizations alone (HR 0.57; 95% CI: 0.32–1.00), though no significant effect was found on all-cause mortality (HR 0.81; 95% CI: 0.58–1.14). RCTs showed a low risk of bias.</p> Conclusion <p>GLP-1 RAs may significantly lower the combined risk of mortality and hospitalization in patients with HFpEF.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年7月10日

查看全文
  • Antony Gonzales-Uribe,
  • Renato Ruiz-Cortez,
  • Nicole Collantes-Silva,
  • Lorenzo Olivero,
  • Raksheeth Agarwal,
  • Sebastian Arambulo-Castillo,
  • Alonso Garcia-Geng,
  • Xiajie Lyu,
  • Daniel Mendoza-Quispe,
  • Victor Becerra-Gonzales,
  • Hoda Butrous

摘要

Background

Pharmacologic therapies for heart failure with preserved ejection fraction (HFpEF) have shown limited efficacy, and the impact of GLP-1 receptor agonists (GLP-1 RAs) remains unclear. This meta-analysis evaluates their effects on mortality and hospitalization in HFpEF.

Methods

We obtained the data from PubMed, Scopus, Embase, and Web of Science for all eligible studies, including clinical trials (RCT) and cohorts comparing GLP-1 RAs to placebo or other hypoglycemic agents in patients with HFpEF published until December 31st, 2024. The Grade and Risk of Bias (ROB) tool assessment was used to evaluate the quality of the evidence. Data on the primary outcome, the composite of all-cause mortality and HF-related hospitalization, was pooled using a random effect meta-analysis with additional subgroup analyses. Risk ratios (RR), hazard ratios (HR), or mean differences with 95% confidence intervals (CI) are presented accordingly.

Results

Six studies (five RCTs, one cohort) including 4043 patients were analyzed. Five studies evaluated semaglutide and one tirzepatide. GLP-1 RAs reduced the composite outcome of all-cause mortality and HF hospitalization by 27% (HR 0.73; 95% CI: 0.60–0.90; I2 = 0%). Subgroup analyses revealed greater benefits in patients with atrial fibrillation. GLP-1 RAs also reduced HF hospitalizations alone (HR 0.57; 95% CI: 0.32–1.00), though no significant effect was found on all-cause mortality (HR 0.81; 95% CI: 0.58–1.14). RCTs showed a low risk of bias.

Conclusion

GLP-1 RAs may significantly lower the combined risk of mortality and hospitalization in patients with HFpEF.

Graphical Abstract